521 related articles for article (PubMed ID: 29216833)
1. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis.
Wongjarupong N; Assavapongpaiboon B; Susantitaphong P; Cheungpasitporn W; Treeprasertsuk S; Rerknimitr R; Chaiteerakij R
BMC Gastroenterol; 2017 Dec; 17(1):149. PubMed ID: 29216833
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.
Clements O; Eliahoo J; Kim JU; Taylor-Robinson SD; Khan SA
J Hepatol; 2020 Jan; 72(1):95-103. PubMed ID: 31536748
[TBL] [Abstract][Full Text] [Related]
3. Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis.
Liu SS; Ma XF; Zhao J; Du SX; Zhang J; Dong MZ; Xin YN
Lipids Health Dis; 2020 May; 19(1):118. PubMed ID: 32475354
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic fatty liver disease is associated with intrahepatic cholangiocarcinoma and not with extrahepatic form: definitive evidence from meta-analysis and trial sequential analysis.
Corrao S; Natoli G; Argano C
Eur J Gastroenterol Hepatol; 2021 Jan; 33(1):62-68. PubMed ID: 32091438
[TBL] [Abstract][Full Text] [Related]
5. Differences in immunohistochemical biomarkers between intra- and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis.
Wiggers JK; Ruys AT; Groot Koerkamp B; Beuers U; ten Kate FJ; van Gulik TM
J Gastroenterol Hepatol; 2014 Aug; 29(8):1582-94. PubMed ID: 24787096
[TBL] [Abstract][Full Text] [Related]
6. Cholangiocarcinoma miscoding in hepatobiliary centres.
Selvadurai S; Mann K; Mithra S; Bridgewater J; Malik H; Khan SA
Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):635-639. PubMed ID: 33032867
[TBL] [Abstract][Full Text] [Related]
7. Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017.
Javle M; Lee S; Azad NS; Borad MJ; Kate Kelley R; Sivaraman S; Teschemaker A; Chopra I; Janjan N; Parasuraman S; Bekaii-Saab TS
Oncologist; 2022 Oct; 27(10):874-883. PubMed ID: 35972334
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus infection and the risk of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma: evidence from a systematic review and meta-analysis of 16 case-control studies.
Li H; Hu B; Zhou ZQ; Guan J; Zhang ZY; Zhou GW
World J Surg Oncol; 2015 Apr; 13():161. PubMed ID: 25903488
[TBL] [Abstract][Full Text] [Related]
9. Association of nonalcoholic fatty liver disease and liver cancer.
Schulz PO; Ferreira FG; Nascimento Mde F; Vieira A; Ribeiro MA; David AI; Szutan LA
World J Gastroenterol; 2015 Jan; 21(3):913-8. PubMed ID: 25624725
[TBL] [Abstract][Full Text] [Related]
10. Cholangiocarcinoma in Germany: Epidemiologic trends and impact of misclassification.
Walter D; Ferstl P; Waidmann O; Trojan J; Hartmann S; Schnitzbauer AA; Zeuzem S; Kraywinkel K
Liver Int; 2019 Feb; 39(2):316-323. PubMed ID: 30176117
[TBL] [Abstract][Full Text] [Related]
11. Non-Alcoholic Steatohepatitis as a Risk Factor for Intrahepatic Cholangiocarcinoma and Its Prognostic Role.
De Lorenzo S; Tovoli F; Mazzotta A; Vasuri F; Edeline J; Malvi D; Boudjema K; Renzulli M; Jeddou H; D'Errico A; Turlin B; Cescon M; Uguen T; Granito A; Lièvre A; Brandi G
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33138044
[TBL] [Abstract][Full Text] [Related]
12. Analysis of metastasis and survival between extrahepatic and intrahepatic cholangiocarcinoma: A large population-based study.
Liao P; Cao L; Chen H; Pang SZ
Medicine (Baltimore); 2021 Apr; 100(16):e25635. PubMed ID: 33879742
[TBL] [Abstract][Full Text] [Related]
13. New epidemiologic trends in cholangiocarcinoma.
Pascale A; Rosmorduc O; Duclos-Vallée JC
Clin Res Hepatol Gastroenterol; 2023 Nov; 47(9):102223. PubMed ID: 37797807
[TBL] [Abstract][Full Text] [Related]
14. Clinical presentation, diagnosis and staging of cholangiocarcinoma.
Forner A; Vidili G; Rengo M; Bujanda L; Ponz-Sarvisé M; Lamarca A
Liver Int; 2019 May; 39 Suppl 1():98-107. PubMed ID: 30831002
[TBL] [Abstract][Full Text] [Related]
15. Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma.
Tóth M; Wehling L; Thiess L; Rose F; Schmitt J; Weiler SME; Sticht C; De La Torre C; Rausch M; Albrecht T; Grabe N; Duwe L; Andersen JB; Köhler BC; Springfeld C; Mehrabi A; Kulu Y; Schirmacher P; Roessler S; Goeppert B; Breuhahn K
BMC Cancer; 2021 Oct; 21(1):1079. PubMed ID: 34615513
[TBL] [Abstract][Full Text] [Related]
16. Clinical treatment of cholangiocarcinoma: an updated comprehensive review.
Elvevi A; Laffusa A; Scaravaglio M; Rossi RE; Longarini R; Stagno AM; Cristoferi L; Ciaccio A; Cortinovis DL; Invernizzi P; Massironi S
Ann Hepatol; 2022; 27(5):100737. PubMed ID: 35809836
[TBL] [Abstract][Full Text] [Related]
17. Intrahepatic Cholangiocarcinoma Developing in Patients with Metabolic Syndrome Is Characterized by Osteopontin Overexpression in the Tumor Stroma.
Cadamuro M; Sarcognato S; Camerotto R; Girardi N; Lasagni A; Zanus G; Cillo U; Gringeri E; Morana G; Strazzabosco M; Campello E; Simioni P; Guido M; Fabris L
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902188
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis.
Trikudanathan G; Navaneethan U; Njei B; Vargo JJ; Parsi MA
Gastrointest Endosc; 2014 May; 79(5):783-9. PubMed ID: 24140129
[TBL] [Abstract][Full Text] [Related]
19. [Research advances of relationship between non-alcoholic fatty liver disease and biliary tract diseases].
Huang RX; Wang BC; Fan JG
Zhonghua Gan Zang Bing Za Zhi; 2017 Aug; 25(8):633-636. PubMed ID: 29056017
[TBL] [Abstract][Full Text] [Related]
20. Association between non-alcoholic fatty liver disease and the risk of biliary tract cancers: A South Korean nationwide cohort study.
Park JH; Hong JY; Kwon M; Lee J; Han K; Han IW; Kang W; Park JK
Eur J Cancer; 2021 Jun; 150():73-82. PubMed ID: 33892409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
